How does amycretin differ from CagriSema?

Amycretin is one molecule engaging both receptors. CagriSema combines two separate molecules, cagrilintide and semaglutide, in one injection.

What evidence supported the move to Phase 3?

A phase 1b/2a randomised study of the subcutaneous form published in the Lancet in July 2025 — early-stage data on safety, tolerability and initial activity.

Does entering Phase 3 mean it works?

No. Phase 3 exists to test that. Compounds enter and fail there routinely.

Research & Regulatory News

Amycretin's Move to Phase 3

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Novo Nordisk advanced amycretin, a unimolecular GLP-1 and amylin receptor agonist, into Phase 3 development in 2026 for both subcutaneous and oral formulations. The supporting subcutaneous data was a phase 1b/2a randomised study published in the Lancet in July 2025.

Key facts

Compound: Amycretin, Novo Nordisk
Class: Unimolecular GLP-1 + amylin receptor agonist
Formulations: Subcutaneous and oral
Supporting study: Phase 1b/2a, Lancet 2025 (PMID 40550231)
Phase 3 start: 2026, obesity and type 2 diabetes
Contrast: CagriSema combines two molecules

What amycretin is

One molecule engaging both the GLP-1 receptor and the amylin receptor. That distinguishes it from CagriSema, which achieves a similar combination by pairing cagrilintide with semaglutide as two separate molecules in one injection. Amycretin is the single-molecule approach to the same pharmacological pairing.

Why the single-molecule route is pursued

One pharmacokinetic profile. Two separate agents each have their own absorption, distribution and clearance, and keeping them matched is a real formulation problem. A single molecule cannot fall out of step with itself — the same argument that motivates the multi-agonist incretins.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

What the published evidence was

Dahl and colleagues reported a phase 1b/2a randomised controlled study of subcutaneous amycretin in the Lancet in July 2025. Phase 1b/2a is early: the questions are safety, tolerability, pharmacokinetics and initial signals of activity, in small numbers over short durations.

What advancing to Phase 3 does and does not indicate

It indicates a sponsor's commercial and scientific judgement that the early data justifies a very large investment. It does not indicate efficacy has been established — that is precisely what Phase 3 exists to test. Compounds enter Phase 3 and fail there routinely, and the danuglipron programme shows that even meeting objectives does not guarantee continuation.

Why the oral formulation is the more interesting half

An orally available peptide is a much harder problem than an oral small molecule, because peptides are digested. Oral semaglutide solves it with an absorption enhancer and strict administration conditions. Whether amycretin's oral form performs adequately in Phase 3 is a more open question than the subcutaneous form's.

What this does not concern

Amycretin is investigational and holds no marketing authorisation anywhere. It is not available outside registered clinical trials, and no research material is related to it or is an alternative to it.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

How does amycretin differ from CagriSema?: Amycretin is one molecule engaging both receptors. CagriSema combines two separate molecules, cagrilintide and semaglutide, in one injection.
What evidence supported the move to Phase 3?: A phase 1b/2a randomised study of the subcutaneous form published in the Lancet in July 2025 — early-stage data on safety, tolerability and initial activity.
Does entering Phase 3 mean it works?: No. Phase 3 exists to test that. Compounds enter and fail there routinely.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum